Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 2999-3010

  Huang, Gloria S ^a,b,c   Brouwer Visser, Jurriaan ^a,b   Ramirez, Marissa J ^b   Kim, Christine H ^a   Hebert, Tiffany M ^b   Lin, Juan ^b   Arias Pulido, Hugo ^d   Qualls, Clifford R ^d   Prossnitz, Eric R ^e   Goldberg, Gary L ^a,c   Smith, Harriet O ^a,c   Horwitz, Susan Band ^b,c  

^a Division of Gynecologic Oncology   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DISCODERMOLIDE; DOXORUBICIN; IXABEPILONE; NVP AEW 541; PACLITAXEL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; VINBLASTINE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CELL STRAIN HEY T30; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953088280     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3233     Document Type: Article

References (38)

1. Giannakakou P, Nakano M, Nicolaou KC, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002; 99:10855-10860
2. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5 Suppl 6:S3-6.
3. Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of β-tubulin. J Biol Chem 1995;270:20235-20238
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667 (Pubitemid 9114288)
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265
6. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22: 7280-7295
7. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001;60:290-301.
8. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005;65:2854-2860
9. Mabuchi S, Ohmichi M, Kimura A, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002;277:33490-33500
10. Gotlieb WH, Bruchim I, Gu J, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2006;100: 389-396
11. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275:661-665
12. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-1606 (Pubitemid 27097389)
13. Rodon J, DeSantos V, Ferry RJ, Jr., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-2588
14. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-239
15. Yang CP, Horwitz SB. Taxol mediates serine phosphorylation of the 66-kDa Shc isoform. Cancer Res 2000;60:5171-5178
16. Lu L, Katsaros D, Wiley A, et al. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol 2006;103:990-995
17. Lu L, Katsaros D, Wiley A, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-α expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006;12:1208-1214
18. Matsuyama R, Togo S, Shimizu D, et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006;119:406-413
19. Alexiadis M, Mamers P, Chu S, Fuller PJ. Insulin-like growth factor, insulin-like growth factor-binding protein-4, and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumors. Int J Gynecol Cancer 2006;16:1973-1979
20. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol 2006;Chapter 15:Unit 15.8.
21. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112 (Pubitemid 20213250)
22. He L, Jagtap PG, Kingston DG, Shen HJ, Orr GA, Horwitz SB. A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry 2000;39:3972-3978
23. Klein LE, Freeze BS, Smith AB III, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 2005;4:501-507
24. Huang GS, Lopez-Barcons L, Freeze BS, et al. Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 2006;12:298-304.
25. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-230
26. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-39695
27. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002;21:8240-8250
28. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-1092 (Pubitemid 34160292)
29. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4:977-986
30. Haluska P, Carboni JM, TenEyck C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-2598
31. Eckstein N, Serva K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009;69:2996-3003.
32. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G. Chemo-resistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-1957
33. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300
34. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-2928 (Pubitemid 34525780)
35. Lancaster JM, Dressman HK, Whitaker RS, et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004;11:51-59
36. Sayer RA, Lancaster JM, Pittman J, et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005;96:355-361
37. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-1072
38. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005;102:7677-7682